Milwaukee – September 22, 2026 -- More than 90% of patients carrying a documented penicillin allergy in their electronic medical records can safely take the drug after clinical evaluation, according to the American Academy of Allergy, Asthma & Immunology (AAAAI), which is marking National Penicillin Allergy Day on September 28 with a push for wider adoption of allergy "de-labeling" protocols.
Inaccurate allergy labels block access to first-line infection treatment
Penicillin remains the most effective therapy for many bacterial infections, yet patients with unverified allergy labels are routinely steered toward alternative antibiotics. The AAAAI states that removing inaccurate labels through evaluation improves patient outcomes, lowers healthcare costs and supports efforts against antimicrobial resistance.
AAAAI directs clinicians to a dedicated Penicillin Allergy Center
The organization has built out the AAAAI Penicillin Allergy Center, offering podcasts, videos, social media graphics and practice resources for medical professionals seeking to implement de-labeling protocols. A companion Penicillin Allergy Position Statement confirms that allergy testing is safe for both children and adults.
Bipartisan PAVE Act would mandate Medicare allergy screening
The Penicillin Allergy Verification and Evaluation (PAVE) Act, introduced in Congress as H.R. 5736 with AAAAI collaboration and bipartisan backing, would require penicillin allergy verification and evaluation to be incorporated into Medicare's Initial Preventative Physical Exam and Annual Wellness Visit. The AAAAI is directing members and the public to its AAAAI Advocate platform to lobby congressional representatives in support of the bill.
Academy expands antimicrobial resistance advocacy agenda
The AAAAI, which represents more than 7,100 allergists, asthma specialists, clinical immunologists and related professionals, is making experts available for media interviews on penicillin allergy and de-labeling ahead of the awareness day. The organization, established in 1943, is also promoting additional advocacy initiatives targeting antibiotic and antimicrobial resistance through its website.